Targeting MTPN sensitizes pancreatic cancer of wild-type BRCA1/2 to Cisplatin-based chemotherapy

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Cancer Gene Therapy

• Publication date

  2025-09-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41417-025-00925-5PMID 40903529
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Harmonizome 3.0: integrated knowledge about genes and proteins from diverse multi-omics resources

  2024cited by this paper
• PubChem 2025 update.

  2024influential reference
• Comparative Toxicogenomics Database’s 20th anniversary: update 2025

  2024influential reference
• ChIP-Atlas 3.0: a data-mining suite to explore chromosome architecture together with large-scale regulome data

  2024cited by this paper
• DrugBank 6.0: the DrugBank Knowledgebase for 2024

  2023influential reference
• JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles

  2023cited by this paper
• Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies.

  2022cited by this paper
• Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.

  2022cited by this paper
• Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs

  2022cited by this paper
• BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors

  2022cited by this paper
• Identification of robust diagnostic and prognostic gene signatures in different grades of gliomas: a retrospective study

  2021cited by this paper
• Survival After Margin-Positive Resection in the Era of Modern Chemotherapy for Pancreatic Cancer: Do Patients Still Benefit?

  2021cited by this paper
• Pancreatic Cancer: A Review.

  2021cited by this paper
• The ATO/miRNA-885-5p/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma

  2021cited by this paper
• IκBα targeting promotes oxidative stress-dependent cell death

  2021cited by this paper
• SKA1 regulates actin cytoskeleton remodelling via activating Cdc42 and influences the migration of pancreatic ductal adenocarcinoma cells

  2020cited by this paper
• Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

  2020cited by this paper
• Therapeutic resistance of pancreatic cancer: Roadmap to its reversal.

  2020cited by this paper
• DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt/GSK3β/Snail pathway

  2020cited by this paper
• DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives

  2020cited by this paper
• Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.

  2020cited by this paper
• KnockTF: a comprehensive human gene expression profile database with knockdown/knockout of transcription factors

  2019cited by this paper
• ChEA3: transcription factor enrichment analysis by orthogonal omics integration

  2019cited by this paper
• hTFtarget: A Comprehensive Database for Regulations of Human Transcription Factors and Their Targets

  2019cited by this paper
• The DisGeNET knowledge platform for disease genomics: 2019 update

  2019influential reference
• Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

  2019cited by this paper
• GTRD: a database on gene transcription regulation—2019 update

  2018cited by this paper
• Recapitulating the clinical scenario of BRCA‐associated pancreatic cancer in pre‐clinical models

  2018cited by this paper
• Scripts

  2018cited by this paper
• GeneHancer: genome-wide integration of enhancers and target genes in GeneCards

  2017influential reference
• TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions

  2017cited by this paper
• The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer

  2017cited by this paper
• GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

  2017cited by this paper
• Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.

  2016cited by this paper
• The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins

  2016cited by this paper
• Pancreatic Cancer: A Review.

  2016cited by this paper
• Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells

  2016cited by this paper
• STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data

  2015influential reference
• Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673.

  2015cited by this paper
• The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models.

  2013cited by this paper
• The complexity of NF-κB signaling in inflammation and cancer

  2013cited by this paper
• Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway.

  2012cited by this paper
• An Integrated Encyclopedia of DNA Elements in the Human Genome

  2012cited by this paper
• NF-κB regulates DNA double-strand break repair in conjunction with BRCA1–CtIP complexes

  2011cited by this paper
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

  2008cited by this paper
• Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

  2008cited by this paper
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

  2008cited by this paper
• c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.

  2007cited by this paper
• Role of BRCA1 and BRCA2 mutations in pancreatic cancer

  2006cited by this paper
• An Unconventional Antigen Translated by a Novel Internal Ribosome Entry Site Elicits Antitumor Humoral Immune Reactions1

  2006cited by this paper
• Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

  2005cited by this paper
• Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs.

  2005cited by this paper
• Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models*

  2004cited by this paper
• DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.

  2003cited by this paper
• Gemcitabine and platinum combinations in pancreatic cancer.

  2002cited by this paper
• Genome maintenance mechanisms for preventing cancer

  2001cited by this paper
• Molecular mechanisms involved in cisplatin cytotoxicity

  2000cited by this paper
• The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*

  2000cited by this paper
• Cardiac Myotrophin Exhibits rel/NF-κB Interacting Activity in Vitro(*)

  1996cited by this paper
• Myotrophin: purification of a novel peptide from spontaneously hypertensive rat heart that influences myocardial growth.

  1990cited by this paper
• Activation of Nuclear Factor-␬ B Is Necessary for Myotrophin-induced Cardiac Hypertrophy

  year unknowncited by this paper

• Investigating the epigenetic modulating potential of gallic acid during ethanol-induced toxicity: In silico and in vitro approaches.

  2026cites this paper